BREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud After Shares Fall Nearly 75%; Investors Encouraged to Contact the Firm

Core Viewpoint - Aldeyra Therapeutics, Inc. is under investigation for potential securities law violations following a significant drop in share price after the FDA issued a second Complete Response Letter for its lead drug candidate reproxalap, citing efficacy concerns and trial design issues [2][4]. Group 1: Company Overview - Aldeyra Therapeutics, Inc. experienced a nearly 75% decline in share price during intraday trading due to the FDA's second Complete Response Letter regarding reproxalap, which is intended for dry eye disease [2]. - The FDA's Complete Response Letter highlighted a failure to demonstrate efficacy and raised concerns about the trial's design, particularly regarding baseline symptom score differences that could affect trial result reliability [2]. Group 2: Legal Investigation - Block & Leviton is investigating whether Aldeyra adequately disclosed risks associated with its clinical data and regulatory approval process, potentially leading to securities law violations [2][4]. - Investors who have incurred losses from their Aldeyra investments are encouraged to contact Block & Leviton for potential recovery options [3][5]. Group 3: Whistleblower Information - Individuals with non-public information about Aldeyra Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 4: Firm's Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].